IN2015MN00045A - - Google Patents

Info

Publication number
IN2015MN00045A
IN2015MN00045A IN45MUN2015A IN2015MN00045A IN 2015MN00045 A IN2015MN00045 A IN 2015MN00045A IN 45MUN2015 A IN45MUN2015 A IN 45MUN2015A IN 2015MN00045 A IN2015MN00045 A IN 2015MN00045A
Authority
IN
India
Prior art keywords
compounds
formula
relates
present
aurora kinase
Prior art date
Application number
Other languages
English (en)
Inventor
Julian Blagg
Vassilios Bavetsias
Andrew S Moore
Spyridon Linardopoulos
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Publication of IN2015MN00045A publication Critical patent/IN2015MN00045A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN45MUN2015 2012-06-21 2013-06-21 IN2015MN00045A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1211021.9A GB201211021D0 (en) 2012-06-21 2012-06-21 Pharmaceutically active compounds
PCT/GB2013/051633 WO2013190319A1 (fr) 2012-06-21 2013-06-21 Composés pharmaceutiquement actifs

Publications (1)

Publication Number Publication Date
IN2015MN00045A true IN2015MN00045A (fr) 2015-10-16

Family

ID=46641296

Family Applications (1)

Application Number Title Priority Date Filing Date
IN45MUN2015 IN2015MN00045A (fr) 2012-06-21 2013-06-21

Country Status (22)

Country Link
US (1) US9447092B2 (fr)
EP (1) EP2864328B8 (fr)
JP (1) JP6159397B2 (fr)
CN (1) CN104470922B (fr)
AU (1) AU2013279040B2 (fr)
BR (1) BR112014032142B1 (fr)
CA (1) CA2876357C (fr)
CY (1) CY1120608T1 (fr)
DK (1) DK2864328T3 (fr)
ES (1) ES2660159T3 (fr)
GB (1) GB201211021D0 (fr)
HR (1) HRP20180386T1 (fr)
HU (1) HUE036048T2 (fr)
IN (1) IN2015MN00045A (fr)
LT (1) LT2864328T (fr)
NO (1) NO2864328T3 (fr)
PL (1) PL2864328T3 (fr)
PT (1) PT2864328T (fr)
RS (1) RS56996B1 (fr)
RU (1) RU2654942C2 (fr)
SI (1) SI2864328T1 (fr)
WO (1) WO2013190319A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522532D0 (en) * 2015-12-21 2016-02-03 Cancer Rec Tech Ltd Novel pyrrolo[3,2-c]pyridine-6-amino derivatives
JP6591036B2 (ja) 2016-02-26 2019-10-16 公益財団法人がん研究会 Hp1の機能に着目した抗癌剤のスクリーニング方法及び評価系
GB2596038B (en) 2020-03-04 2022-12-14 Ellipses Pharma Ltd Salts and polymorphic forms of (6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-B]pyridine)
GB2592622B (en) 2020-03-04 2022-08-03 Ellipses Pharma Ltd Formulations of a dual aurora kinase/FLT3 inhibitor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
KR20030013433A (ko) 2000-05-31 2003-02-14 아스트라제네카 아베 혈관 손상 활성을 가진 인돌 유도체
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
EP1301497A1 (fr) 2000-07-07 2003-04-16 Angiogene Pharmaceuticals Limited Derives de colchinol utilises comme agents de degradation vasculaire
US7064215B2 (en) * 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
CN102127078A (zh) * 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
EP1963315B1 (fr) * 2005-12-22 2014-10-08 Cancer Research Technology Limited Inhibiteurs d'enzymes
CN101616920A (zh) * 2007-01-30 2009-12-30 比奥根艾迪克Ma公司 1-H-吡唑并(3,4b)嘧啶衍生物及其作为有丝分裂激酶调节剂的用途
WO2009001021A1 (fr) 2007-06-26 2008-12-31 Chroma Therapeutics Ltd. Dérivés d'imidazopyridine utiles comme inhibiteurs d'enzymes pour le traitement de maladies de prolifération des cellules et auto-immunes
EP2320895A2 (fr) * 2008-07-03 2011-05-18 Exelixis, Inc. Modulateurs de cdk
US9346807B2 (en) * 2010-09-14 2016-05-24 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture

Also Published As

Publication number Publication date
PL2864328T3 (pl) 2018-06-29
SI2864328T1 (en) 2018-04-30
CY1120608T1 (el) 2019-12-11
PT2864328T (pt) 2018-03-12
AU2013279040B2 (en) 2017-11-16
JP6159397B2 (ja) 2017-07-05
CN104470922B (zh) 2016-08-24
US9447092B2 (en) 2016-09-20
JP2015520222A (ja) 2015-07-16
GB201211021D0 (en) 2012-08-01
AU2013279040A1 (en) 2015-01-29
RU2015101702A (ru) 2016-08-10
BR112014032142A2 (pt) 2017-06-27
RS56996B1 (sr) 2018-05-31
LT2864328T (lt) 2018-04-10
DK2864328T3 (en) 2018-03-12
HRP20180386T1 (hr) 2018-04-20
CN104470922A (zh) 2015-03-25
ES2660159T3 (es) 2018-03-21
EP2864328B1 (fr) 2017-12-06
US20150266868A1 (en) 2015-09-24
NO2864328T3 (fr) 2018-05-05
CA2876357C (fr) 2020-07-14
BR112014032142B1 (pt) 2022-03-03
RU2654942C2 (ru) 2018-05-25
CA2876357A1 (fr) 2013-12-27
HUE036048T2 (hu) 2018-06-28
EP2864328A1 (fr) 2015-04-29
EP2864328B8 (fr) 2018-01-24
WO2013190319A1 (fr) 2013-12-27

Similar Documents

Publication Publication Date Title
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
MX360634B (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos.
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
IN2014MN00988A (fr)
MX2015017861A (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
MD4666B1 (ro) Inhibitori ai Syk
TN2014000128A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
IN2014MN01754A (fr)
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
MX2014014106A (es) Derivados de acido 7-oxo-tiazolopiridinocarbonico y su uso en el tratamiento, disminucion o prevencion de una enfermedad viral.
NZ711424A (en) Pyridine derivatives as soft rock inhibitors
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
MX2013012588A (es) Inhibidores de cinasa.
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
GB201302704D0 (en) Therapeutic compounds
MX2014003803A (es) Derivados de acido heteroarilo hidroxamico y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
TN2013000533A1 (en) Topical ophthalmological pharmaceutical composition containing regorafenib
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
PH12017500595A1 (en) Aldosterone synthase inhibitors
CY1120608T1 (el) Φαρμακευτικως δραστικες ενωσεις
PH12014501943A1 (en) Novel compounds for the treatment of dyslipidemia and related diseases
IN2013DN02555A (fr)
PH12015501407A1 (en) Topical opthalmological pharmaceutical composition containing regorafenib
MX2015008292A (es) Derivados de naftiridinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.